MedisourceRx: 503B compounder profile (Hims-owned)

MedisourceRx is unusual in this directory: it’s a compounding facility owned by a telehealth company. It’s the clearest example of vertical integration in compounded GLP-1s — the brand that sells the prescription also owns the pharmacy that fills it.

Facility & ownership

MedisourceRx is a 503B outsourcing facility in Los Alamitos, CA, listed on the FDA Registered Outsourcing Facilities list [1]. Hims & Hers acquired it in 2024: per the company’s SEC filing, “we acquired Seaview Enterprises, LLC (d/b/a MedisourceRx)… a licensed 503B compounding outsourcing facility, which compounds products primarily for Hims & Hers customers” [2]. So it is a Hims-owned subsidiary, not an independent third-party pharmacy. We could not confirm PCAB accreditation in ACHC’s registry.

What they compound

Injectable compounded semaglutide, produced primarily for Hims & Hers’ weight-loss customers [2]. (Hims’ oral compounded semaglutide is filled by a separate pharmacy, Strive.)

Regulatory record

MedisourceRx received an FDA warning letter dated December 12, 2025 [3]. Per FDA, the letter centered on failures in adverse-event reporting requirements for the facility. A warning letter is a formal FDA enforcement notice over significant violations. Stated as FDA’s findings; dated to our review.

The read

Worth knowing for anyone using Hims’ injectable GLP-1: the pharmacy behind it is Hims itself, and it carries a recent FDA warning letter. This isn’t a pharmacy consumers choose directly — it’s the in-house supplier for one telehealth brand — but it’s the sharpest illustration of how telehealth compounded-GLP-1 supply is becoming vertically integrated.

References

1. FDA — Registered Outsourcing Facilities (503B) list. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (accessed 2026-07-04)
2. Hims & Hers Health, Inc. — Form 10-K (FY2024), acquisition of Seaview Enterprises, LLC (d/b/a MedisourceRx). https://www.sec.gov/Archives/edgar/data/1773751/000177375125000062/hims-20241231.htm (accessed 2026-07-04)
3. FDA — Warning Letter to MedisourceRx (#717970, 2025-12-12). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medisourcerx-717970-12122025 (accessed 2026-07-04)